121
Participants
Start Date
March 15, 2023
Primary Completion Date
January 23, 2025
Study Completion Date
January 23, 2025
Tislelizumab
Administered as an intravenous infusion
Ociperlimab
Administered as an intravenous infusion
LBL-007
Administered as an intravenous infusion
Cisplatin
Administered as an intravenous infusion
Carboplatin
Administered as an intravenous infusion
Pemetrexed
Administered as an intravenous infusion
Paclitaxel
Administered as an intravenous infusion
Beijing Cancer Hospital, Beijing
Liaoning Cancer Hospital and Institute, Shenyang
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai Pulmonary Hospital, Shanghai
The First Affiliated Hospital of Wannan Medical College, Wuhu
Shandong Cancer Hospital, Jinan
Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo
The First Affiliated Hospital of Nanchang University Branch Xianghu, Nanchang
Fujian Medical University Union Hospital, Fuzhou
Hunan Cancer Hospital, Changsha
Hubei Cancer Hospital, Wuhan
Anyang Cancer Hospital, Anyang
The First Affiliated Hospital of Guangzhou Medical Universitydatansha Hospital), Guangzhou
The Tumor Hospital Affiliated to Guangxi Medical University, Nanning
Lead Sponsor
BeiGene
INDUSTRY